1. Introduction to LLS Therapy Acceleration Program
May 2019

2. Blood Cancers
Every 3 minutes someone in the US is diagnosed with a blood cancer.
More than one third of blood cancer patients do not survive five years after diagnosis.
Despite improved outcomes, we need to do more!

3. Our Mission
Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families
More than $1.2 billion invested in research
Unparalleled patient support and education services
Advocacy to accelerate cures and access

4. Research Grant Programs
LLS Research focuses on discovering and developing therapies to positively impact care for blood cancer patients
Patient Education,
Access & Advocacy
Research Grant Programs
Therapy
Acceleration
Program®
Beat AML Initiative
Discovery
Development
Commercialize

5. Therapy Acceleration Program (TAP)
Strategic initiative established in 2007
Accelerate high-risk innovative blood cancer therapeutics
Bridge the gap - especially phase I/II
Academic programs
Biopharma programs
Meeting LLS Mission is first priority
Generating ROI to further fund LLS Mission is secondary
Highest risk to progress

6. LTherapy Acceleration Program (TAP) Supports Emerging New Therapies
TAP – Progress to Date
>60 projects / >$120 M invested to date
17 active programs
3 FDA-Approved Therapies
Vyxeos (AML)
Yescarta (DLBCL, tFL, PMBCL)
Elzonris (BPDCN)
Promising clinical data with
CD47 mAb (DLBCL, FL)1 ,
anti-CD123-diphtheria toxin (BPDCN)2
duvelisib (PTCL) 3
Advani et al NEJM. 379:
Pemmaraju ASH 2018, abstract 765
Horwitz et al Blood. 131:
= new

7. TAP Committee Endorsement
LLS TAP Process
Internal Diligence
Expert Review
TAP Committee Endorsement
Contract Execution
Active Project
Open to funding application year round
All hematological indications
Therapeutics, diagnostics & supportive care
Typically $2-8 M dollars (co-funding for companies)
– equity or asset based
Applicants fill out 1-page Inquiry Form to start the process
How to apply for TAP:

8. Key Criteria High Unmet Medical Need Innovative Science First-in-Class
Clinical Proof of Concept Study
Strong Intellectual Property Position
Competent Management Team
Adequate Co-Funds to Finish Proposed Studies

9. LLS TAP Funding is Competitive

10. TAP Portfolio Company Research Highlights
Stemline: Approved Therapy
Affimed:
Forty Seven: Exciting Published Data

11. TAP is Bridging the Gap for Biotech

12. Select Active Projects in TAP Portfolio

13. LLS TAP Investment: Patient Testimonial
Emily Dumler
Emily, a 32-year-old mother of three young children, was diagnosed with non- Hodgkin lymphoma in August After a whirlwind of intense treatments over the next two years including chemotherapy, a stem cell transplant and months of hospitalization, Emily relapsed soon after each treatment. In January 2015, Emily was given a devastating prognosis – doctors said she had six months to live. 
Emily received a glimmer of hope when doctors told her of a potential new treatment. In July 2015, Emily became the third patient in the world enrolled in Kite Pharma’s clinical trial for a lifesaving treatment called CAR T-cell therapy that was made possible by LLS funding. The revolutionary therapy was a success!
Emily has been in remission for more than two years and today, she enjoys spending time with her family and sharing her story publicly to help others. When she learned that LLS played a major role in the funding of her treatment, she became a devoted volunteer. She raised funds through the Light The Night campaign and was the 2017 Woman of the Year in Kansas City, raising $160,000, a record for that Chapter.   The CAR T-cell immunotherapy that saved Emily was FDA approved in She hopes to continue to spread awareness and help raise funds for lifesaving treatments like the one that saved her own life.

14. We have one goal: A world without blood cancers
Thank you
We have one goal: A world without blood cancers